Pharmaceuticals cost more in America than in any other developed nation. But copying Europe’s price controls with Most Favored Nation pricing (MFN) will not fix that problem. Washington should instead focus on a reform that is already reducing patients’ prices: direct-to-consumer (DTC) pharmaceutical sales.
